Biosimilar insulines – new possibilities of diabetes treatment

Česká verzia

Authors: Jan Škrha
Authors place of work: III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in the journal: Vnitř Lék 2015; 61(4): 301-303
Category: Reviews

Summary

Biosimilar insulins are biological drugs with the effect similar to reference insulins. Documented safety and efficacy are the main demand for their clinical utility. The subsequent introduction into clinical practice will be followed by more frequent use which will need longterm evaluation of their effect on glycemia and eventual side effects as well.

Key words:
biosimilar insulin – clinical utility – efficacy – reference insulin – safety

Zdroje

1. Slíva J. Co jsou a co nám přinášejí biosimilars? Vnitř Lék 2015; 61(2): 143–145.

2. DeVries JH, Gough SCL, Kiljanski J et al. Biosimilar insulins: a European perspective. Diabetes Obes Metab 2014; Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12410>.

3. Edelman S, Polonsky WH, Parkin CG. Biosimilar insulins are coming: what they are, what you need to know? Curr Med Res Opin 2014; 30(11): 2217–2222.

4. Blumer I, Edelman S. Biosimilar insulins are coming: the top 10 things you should know. Postgrad Med 2014; 126(3): 107–110.

5. Owens DR, Landgraf W, Schmidt A et al. The emergence of biosimilar insulin preparations – a cause for concern? Diabetes Technol Ther 2012; 14(11): 989–996.

6. Grzeszczak W, Bijos P, Borkowski M et al. A comparison of the efficacy and safety in patients with type 2 diabetes mellitus managed with premixed human insulin (Gensulin M30) versus pre-mixed insulin aspart 30/70 (NovoMix 30). Diabet Dosw Klin 2010; 10: 53–59.

7. Verma M, Hazra P, Iyer H et al. Basalog^® is similar to Lantus^® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. Int J Diabetes Dev Ctries 2011; 31(1): 26–31.

8. Heinemann L, Hompesch M. Biosimilar insulins: how simuilar is similar? J Diabetes Sci Technol 2011; 5(3): 741–754.

9. Gough S. Biosimilar insulins: opportunities and challenges. Practical Diabetes 2013; 30(4): 146–147.

10. Wilkins AR, Venkat MV, Brown AS et al. Patient perspectives on biosimilar insulin. J Diabetes Sci Technol 2014; 8(1): 23–25.